Bergen, Norway, 21st May 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that BerGenBio CEO Mr. Richard Godfrey is presenting at the following virtual conference:
ABGSC Life Science Summit, virtual
Date: 25 May
Live presentation at 10.30hrs CET
The presentation will be made available on the Company website: www.bergenbio.com/investors/presentations/
